Exciva key facts
as of Oct 2026- Developer of antitussive medication designed to address both the neurological and psychological aspects of behavioral and psychological symptoms.
- Exciva is valued at approximately $16.4M as of Oct 2026 (last reported valuation).
- It has raised $70.1M; the latest was Later Stage VC ($59.7M) in Jan 2026.
- Notable investors include EQT Life Sciences, Modi Ventures, Andera Partners, LBBW Venture Capital, LifeArc — 9 tracked in total.
- Status: Privately Held (backing).
Exciva's last reported valuation, Oct 2021. Nothing priced has surfaced since.
- ·Watch Exciva: the Monday email on marks, rounds and moves
Exciva funding rounds
No funding rounds for Exciva are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Exciva valuation
Exciva's last reported valuation was $16.4 million in Oct 2021. No priced round, secondary trade or fund mark has surfaced since.
Exciva investors
9 investors are on record for Exciva, including EQT Life Sciences, Modi Ventures, Andera Partners and LBBW Venture Capital.
About Exciva
Developer of antitussive medication designed to address both the neurological and psychological aspects of behavioral and psychological symptoms. The company specializes in developing disease-modifying therapies, cures, prophylactics, supplements, formulations, and methods for making and using such compositions, enabling the healthcare industry to access its program for rescuing and repurposing approved drugs for new indications and uses.
- Sector
- Healthcare
- HQ
- Heidelberg, Germany
- Founded
- 2015
- Employees
- 5
- Website
- exciva.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.